298(top 100%)
PR articles
73.6K(top 0.1%)
PR citations
122(top 100%)
PR h-index
132(top 100%)
h-index
458
documents
95.0K
doc citations
5.1K
citing journals
100
times ranked

Publications

299 PR articles • 78,767 PR citations • Sorted by year • Download PDF (PDF by citations)
Sort: Year | PR Citations
#ArticleIFPR CitationsLinks
1Chemotherapy Drives Tertiary Lymphoid Structures That Correlate with ICI-Responsive TCF1+CD8+ T Cells in Metastatic Ovarian Cancer
Clinical Cancer Research, 2025, 31, 164-180
6.915Citations (PDF)
2Molecular determinants of immunogenic cell death elicited by radiation therapy
Immunological Reviews, 2024, 321, 20-32
6.634Citations (PDF)
3Immunosurveillance in clinical cancer management
Ca-A Cancer Journal for Clinicians, 2024, 74, 187-202
260.494Citations (PDF)
4Non-mutational neoantigens in disease
Nature Immunology, 2024, 25, 29-40
24.231Citations (PDF)
5A guideline on the molecular ecosystem regulating ferroptosis
Nature Cell Biology, 2024, 26, 1447-1457
16.9196Citations (PDF)
6Tertiary lymphoid structures and B cells determine clinically relevant T cell phenotypes in ovarian cancer
Nature Communications, 2024, 15,
13.966Citations (PDF)
7Immunological aspects of central neurodegeneration
Cell Discovery, 2024, 10,
9.614Citations (PDF)
8Targeting immunogenic cell stress and death for cancer therapy
Nature Reviews Drug Discovery, 2024, 23, 445-460
82.4321Citations (PDF)
9Serine Depletion Promotes Antitumor Immunity by Activating Mitochondrial DNA-Mediated cGAS-STING Signaling
Cancer Research, 2024, 84, 2645-2659
0.637Citations (PDF)
10Iron Chelation Therapy Elicits Innate Immune Control of Metastatic Ovarian Cancer
Cancer Discovery, 2024, 14, 1901-1921
25.621Citations (PDF)
11Epigenetic control of immunoevasion in cancer stem cells
Trends in Cancer, 2024, 10, 1052-1071
10.613Citations (PDF)
12The hallmarks of cancer immune evasion
Cancer Cell, 2024, 42, 1825-1863
38.5347Citations (PDF)
13Immunogenic cell death in cancer: concept and therapeutic implications
Journal of Translational Medicine, 2023, 21,
6.6132Citations (PDF)
14Type I interferon signaling in malignant blasts contributes to treatment efficacy in AML patients
Cell Death and Disease, 2023, 14,
8.722Citations (PDF)
15The DNA Damage Response and Inflammation in Cancer
Cancer Discovery, 2023, 13, 1521-1545
25.675Citations (PDF)
16Apoptotic cell death in disease—Current understanding of the NCCD 2023
Cell Death and Differentiation, 2023, 30, 1097-1154
13.7300Citations (PDF)
17Radiation therapy improves CAR T cell activity in acute lymphoblastic leukemia
Cell Death and Disease, 2023, 14,
8.729Citations (PDF)
18Emerging evidence for adapting radiotherapy to immunotherapy
Nature Reviews Clinical Oncology, 2023, 20, 543-557
75.5289Citations (PDF)
19Updates on radiotherapy-immunotherapy combinations: Proceedings of 6 <sup>th</sup> annual ImmunoRad conference
OncoImmunology, 2023, 12,
5.511Citations (PDF)
20BCL2 Inhibition Reveals a Dendritic Cell–Specific Immune Checkpoint That Controls Tumor Immunosurveillance
Cancer Discovery, 2023, 13, 2448-2469
25.655Citations (PDF)
21Radiopharmaceuticals as combinatorial partners for immune checkpoint inhibitors
Trends in Cancer, 2023, 9, 968-981
10.615Citations (PDF)
22Control of host mitochondria by bacterial pathogens
Trends in Microbiology, 2022, 30, 452-465
8.348Citations (PDF)
23Immunogenic cell stress and death
Nature Immunology, 2022, 23, 487-500
24.21,140Citations (PDF)
24Immunological control of ovarian carcinoma by chemotherapy and targeted anticancer agents
Trends in Cancer, 2022, 8, 426-444
10.628Citations (PDF)
25Targeting oncogene and non-oncogene addiction to inflame the tumour microenvironment
Nature Reviews Drug Discovery, 2022, 21, 440-462
82.4130Citations (PDF)
26A loss-of-function polymorphism in <i>ATG16L1</i> compromises therapeutic outcome in head and neck carcinoma patients
OncoImmunology, 2022, 11,
5.56Citations (PDF)
27Myeloid-Derived Suppressor Cells and Radiotherapy
Cancer Immunology Research, 2022, 10, 545-557
4.268Citations (PDF)
28Restored Ketosis Drives Anticancer Immunity in Colorectal Cancer
Cancer Research, 2022, 82, 1464-1466
0.63Citations (PDF)
29An Autologous Dendritic Cell Vaccine Promotes Anticancer Immunity in Patients with Ovarian Cancer with Low Mutational Burden and Cold Tumors
Clinical Cancer Research, 2022, 28, 3053-3065
6.946Citations (PDF)
30Developing antisense oligonucleotides for a TECPR2 mutation-induced, ultra-rare neurological disorder using patient-derived cellular models
Molecular Therapy - Nucleic Acids, 2022, 29, 189-203
5.69Citations (PDF)
31Mitochondrial control of inflammation
Nature Reviews Immunology, 2022, 23, 159-173
56.7774Citations (PDF)
32PDIA3 epitope-driven immune autoreactivity contributes to hepatic damage in type 2 diabetes
Science Immunology, 2022, 7,
13.545Citations (PDF)
33Possible mechanisms of cancer prevention by nicotinamide
British Journal of Pharmacology, 2021, 178, 2034-2040
6.514Citations (PDF)
34Autophagy in the cancer-immunity dialogue
Advanced Drug Delivery Reviews, 2021, 169, 40-50
15.669Citations (PDF)
35Immunomodulation by targeted anticancer agents
Cancer Cell, 2021, 39, 310-345
38.5194Citations (PDF)
36LTX-315-enabled, radiotherapy-boosted immunotherapeutic control of breast cancer by NK cells
OncoImmunology, 2021, 10,
5.538Citations (PDF)
37Radiotherapy Delivered before CDK4/6 Inhibitors Mediates Superior Therapeutic Effects in ER+ Breast Cancer
Clinical Cancer Research, 2021, 27, 1855-1863
6.964Citations (PDF)
38TIM-3 levels correlate with enhanced NK cell cytotoxicity and improved clinical outcome in AML patients
OncoImmunology, 2021, 10,
5.543Citations (PDF)
39Intratumoral heterogeneity in cancer progression and response to immunotherapy
Nature Medicine, 2021, 27, 212-224
39.5684Citations (PDF)
40Immune checkpoint inhibitor–associated myocarditis: manifestations and mechanisms
Journal of Clinical Investigation, 2021, 131,
10.7171Citations (PDF)
41Radiotherapy-exposed CD8+ and CD4+ neoantigens enhance tumor control
Journal of Clinical Investigation, 2021, 131,
10.7203Citations (PDF)
42A naturally occurring mutation in ATP synthase subunit c is associated with increased damage following hypoxia/reoxygenation in STEMI patients
Cell Reports, 2021, 35, 108983
6.432Citations (PDF)
43Pleiotropic consequences of metabolic stress for the major histocompatibility complex class II molecule antigen processing and presentation machinery
Immunity, 2021, 54, 721-736.e10
23.349Citations (PDF)
44Immunofluorescence microscopy-based assessment of cytosolic DNA accumulation in mammalian cells
STAR Protocols, 2021, 2, 100488
1.213Citations (PDF)
45Could Protons Promote Tumor Control by Avoiding Lymphopenia?
Journal of Thoracic Oncology, 2021, 16, e39-e41
2.24Citations (PDF)
46ATP and cancer immunosurveillance
EMBO Journal, 2021, 40,
7.4194Citations (PDF)
47Targeting Cancer Heterogeneity with Immune Responses Driven by Oncolytic Peptides
Trends in Cancer, 2021, 7, 557-572
10.667Citations (PDF)
48Autophagy in major human diseases
EMBO Journal, 2021, 40,
7.41,337Citations (PDF)
49Dendritic cell-based immunotherapy (DCVAC/OvCa) combined with second-line chemotherapy in platinum-sensitive ovarian cancer (SOV02): A randomized, open-label, phase 2 trial
Gynecologic Oncology, 2021, 162, 652-660
3.137Citations (PDF)
50Profiling of immune dysfunction in COVID-19 patients allows early prediction of disease progression
Life Science Alliance, 2021, 4, e202000955
2.669Citations (PDF)
51Trial watch: intratumoral immunotherapy
OncoImmunology, 2021, 10,
5.553Citations (PDF)
52Immunological configuration of ovarian carcinoma: features and impact on disease outcome
2021, 9, e002873
44Citations (PDF)
53Radiotherapy as a tool to elicit clinically actionable signalling pathways in cancer
Nature Reviews Clinical Oncology, 2021, 19, 114-131
75.5184Citations (PDF)
54Autophagy in hepatic adaptation to stress
Journal of Hepatology, 2020, 72, 183-196
3.6139Citations (PDF)
55Trial watch: STING agonists in cancer therapy
OncoImmunology, 2020, 9,
5.5207Citations (PDF)
56Trial watch: IDO inhibitors in cancer therapy
OncoImmunology, 2020, 9,
5.5144Citations (PDF)
57Detection of immunogenic cell death and its relevance for cancer therapy
Cell Death and Disease, 2020, 11,
8.7906Citations (PDF)
58Immunostimulation with chemotherapy in the era of immune checkpoint inhibitors
Nature Reviews Clinical Oncology, 2020, 17, 725-741
75.51,140Citations (PDF)
59Trial Watch: experimental TLR7/TLR8 agonists for oncological indications
OncoImmunology, 2020, 9,
5.590Citations (PDF)
60Immunoprophylactic and immunotherapeutic control of hormone receptor-positive breast cancer
Nature Communications, 2020, 11,
13.9108Citations (PDF)
61Mitochondrial DNA drives abscopal responses to radiation that are inhibited by autophagy
Nature Immunology, 2020, 21, 1160-1171
24.2323Citations (PDF)
62Converging focal radiation and immunotherapy in a preclinical model of triple negative breast cancer: contribution of VISTA blockade
OncoImmunology, 2020, 9,
5.551Citations (PDF)
63M2-like macrophages dictate clinically relevant immunosuppression in metastatic ovarian cancer
2020, 8, e000979
96Citations (PDF)
64Ca2+ Fluxes and Cancer
Molecular Cell, 2020, 78, 1055-1069
13.4219Citations (PDF)
65Trial watch: TLR3 agonists in cancer therapy
OncoImmunology, 2020, 9,
5.5147Citations (PDF)
66Trial watch: chemotherapy-induced immunogenic cell death in immuno-oncology
OncoImmunology, 2020, 9,
5.5200Citations (PDF)
67Immunomodulation by anticancer cell cycle inhibitors
Nature Reviews Immunology, 2020, 20, 669-679
56.7129Citations (PDF)
68Noncanonical Cell Fate Regulation by Bcl-2 Proteins
Trends in Cell Biology, 2020, 30, 537-555
12.394Citations (PDF)
69Consensus guidelines for the definition, detection and interpretation of immunogenic cell death
2020, 8, e000337
889Citations (PDF)
70Calreticulin and cancer
Cell Research, 2020, 31, 5-16
12.5340Citations (PDF)
71Calreticulin exposure on malignant blasts correlates with improved natural killer cell-mediated cytotoxicity in acute myeloid leukemia patients
Haematologica, 2020, 105, 1868-1878
4.148Citations (PDF)
72Acyl-CoA-Binding Protein Is a Lipogenic Factor that Triggers Food Intake and Obesity
Cell Metabolism, 2019, 30, 754-767.e9
26.2105Citations (PDF)
73Extracorporeal photochemotherapy induces bona fide immunogenic cell death
Cell Death and Disease, 2019, 10,
8.778Citations (PDF)
74Trial watch: dendritic cell vaccination for cancer immunotherapy
OncoImmunology, 2019, 8, 1638212
5.5149Citations (PDF)
75Optimising efficacy and reducing toxicity of anticancer radioimmunotherapy
Lancet Oncology, The, 2019, 20, e452-e463
26.0194Citations (PDF)
76Macrophages and Metabolism in the Tumor Microenvironment
Cell Metabolism, 2019, 30, 36-50
26.21,533Citations (PDF)
77Apoptotic caspases inhibit abscopal responses to radiation and identify a new prognostic biomarker for breast cancer patients
OncoImmunology, 2019, 8, e1655964
5.5129Citations (PDF)
78Pharmacological modulation of nucleic acid sensors — therapeutic potential and persisting obstacles
Nature Reviews Drug Discovery, 2019, 18, 845-867
82.4172Citations (PDF)
79Treatment recommendations to cancer patients in the context of FDA guidance for next generation sequencing
BMC Medical Informatics and Decision Making, 2019, 19,
3.318Citations (PDF)
80Next generation sequencing of PD-L1 for predicting response to immune checkpoint inhibitors
2019, 7,
79Citations (PDF)
81Proliferative potential and resistance to immune checkpoint blockade in lung cancer patients
2019, 7,
81Citations (PDF)
82Autophagy-Independent Functions of the Autophagy Machinery
Cell, 2019, 177, 1682-1699
34.1801Citations (PDF)
83Toward a comprehensive view of cancer immune responsiveness: a synopsis from the SITC workshop
2019, 7,
75Citations (PDF)
84TIM-3 Dictates Functional Orientation of the Immune Infiltrate in Ovarian Cancer
Clinical Cancer Research, 2019, 25, 4820-4831
6.998Citations (PDF)
85Lethal Poisoning of Cancer Cells by Respiratory Chain Inhibition plus Dimethyl α-Ketoglutarate
Cell Reports, 2019, 27, 820-834.e9
6.443Citations (PDF)
86Stress responses in stromal cells and tumor homeostasis
2019, 200, 55-68
29Citations (PDF)
87Trial watch: dietary interventions for cancer therapy
OncoImmunology, 2019, 8, e1591878
5.564Citations (PDF)
88Metabolic enzymes expressed by cancer cells impact the immune infiltrate
OncoImmunology, 2019, 8, e1571389
5.518Citations (PDF)
89Mutational and Antigenic Landscape in Tumor Progression and Cancer Immunotherapy
Trends in Cell Biology, 2019, 29, 396-416
12.383Citations (PDF)
90Today's Special on the Anticancer Menu: Immunomodulation by Antifolates
Clinical Cancer Research, 2019, 25, 6890-6892
6.91Citations (PDF)
91Calreticulin exposure correlates with robust adaptive antitumor immunity and favorable prognosis in ovarian carcinoma patients
2019, 7,
67Citations (PDF)
92WNT Signaling in Cancer Immunosurveillance
Trends in Cell Biology, 2019, 29, 44-65
12.3211Citations (PDF)
93Akt‐mediated phosphorylation of <scp>MICU</scp> 1 regulates mitochondrial Ca <sup>2+</sup> levels and tumor growth
EMBO Journal, 2019, 38,
7.4105Citations (PDF)
94Immunological impact of cell death signaling driven by radiation on the tumor microenvironment
Nature Immunology, 2019, 21, 120-134
24.2323Citations (PDF)
95Heterogeneous cellular effects of α-ketoglutarate esters
Aging, 2019, 11, 3412-3413
2.52Citations (PDF)
96The autophagic network and cancer
Nature Cell Biology, 2018, 20, 243-251
16.9274Citations (PDF)
97Trial Watch: Immunostimulation with recombinant cytokines for cancer therapy
OncoImmunology, 2018, 7,
5.548Citations (PDF)
98Molecular mechanisms of cell death: recommendations of the Nomenclature Committee on Cell Death 2018
Cell Death and Differentiation, 2018, 25, 486-541
13.75,678Citations (PDF)
99Emerging biomarkers for the combination of radiotherapy and immune checkpoint blockers
Seminars in Cancer Biology, 2018, 52, 125-134
14.156Citations (PDF)
100SnapShot: CGAS-STING Signaling
Cell, 2018, 173, 276-276.e1
34.1137Citations (PDF)
101Analytical Validation of a Next-Generation Sequencing Assay to Monitor Immune Responses in Solid Tumors
Journal of Molecular Diagnostics, 2018, 20, 95-109
2.670Citations (PDF)
102Guidelines and recommendations on yeast cell death nomenclature
Microbial Cell, 2018, 5, 4-31
3.1185Citations (PDF)
103Mature dendritic cells correlate with favorable immune infiltrate and improved prognosis in ovarian carcinoma patients
2018, 6,
181Citations (PDF)
104Linking cellular stress responses to systemic homeostasis
Nature Reviews Molecular Cell Biology, 2018, 19, 731-745
78.9472Citations (PDF)
105Trial Watch: Toll-like receptor agonists in cancer immunotherapy
OncoImmunology, 2018, 7, e1526250
5.5208Citations (PDF)
106Trial watch: Peptide-based vaccines in anticancer therapy
OncoImmunology, 2018, 7, e1511506
5.5141Citations (PDF)
107The hallmarks of successful anticancer immunotherapy
Science Translational Medicine, 2018, 10,
12.7510Citations (PDF)
108Cytosolic DNA Sensing in Organismal Tumor Control
Cancer Cell, 2018, 34, 361-378
38.5240Citations (PDF)
109Modeling Tumor Immunology and Immunotherapy in Mice
Trends in Cancer, 2018, 4, 599-601
10.683Citations (PDF)
110Predicting response to checkpoint inhibitors in melanoma beyond PD-L1 and mutational burden
2018, 6,
139Citations (PDF)
111Trial Watch: Oncolytic viro-immunotherapy of hematologic and solid tumors
OncoImmunology, 2018, 7, e1503032
5.576Citations (PDF)
112Targeting mitochondria for cardiovascular disorders: therapeutic potential and obstacles
Nature Reviews Cardiology, 2018, 16, 33-55
37.5266Citations (PDF)
113Mitophagy: Permitted by Prohibitin
Current Biology, 2017, 27, R73-R76
3.67Citations (PDF)
114DNA Damage in Stem Cells
Molecular Cell, 2017, 66, 306-319
13.4313Citations (PDF)
115Pharmacological modulation of autophagy: therapeutic potential and persisting obstacles
Nature Reviews Drug Discovery, 2017, 16, 487-511
82.4779Citations (PDF)
116Molecular definitions of autophagy and related processes
EMBO Journal, 2017, 36, 1811-1836
7.41,507Citations (PDF)
117Autophagy in natural and therapy-driven anticancer immunosurveillance
Autophagy, 2017, 13, 2163-2170
14.060Citations (PDF)
118Autophagy and Mitophagy in Cardiovascular Disease
Circulation Research, 2017, 120, 1812-1824
12.5782Citations (PDF)
119Mitochondrial permeability transition involves dissociation of F<sub>1</sub><scp>F<sub>O</sub> ATP</scp> synthase dimers and C‐ring conformation
EMBO Reports, 2017, 18, 1077-1089
5.2183Citations (PDF)
120Necroptosis: Mechanisms and Relevance to Disease
Annual Review of Pathology: Mechanisms of Disease, 2017, 12, 103-130
31.4633Citations (PDF)
121Trial watch: Immunogenic cell death induction by anticancer chemotherapeutics
OncoImmunology, 2017, 6, e1386829
5.5241Citations (PDF)
122Immune recognition of irradiated cancer cells
Immunological Reviews, 2017, 280, 220-230
6.686Citations (PDF)
123Trial Watch: Immunostimulatory monoclonal antibodies for oncological indications
OncoImmunology, 2017, 6, e1371896
5.538Citations (PDF)
124Trial watch: Immune checkpoint blockers for cancer therapy
OncoImmunology, 2017, 6, e1373237
5.567Citations (PDF)
125Trial Watch: Adoptively transferred cells for anticancer immunotherapy
OncoImmunology, 2017, 6, e1363139
5.564Citations (PDF)
126Control of Metastasis by NK Cells
Cancer Cell, 2017, 32, 135-154
38.5696Citations (PDF)
127Trial watch: DNA-based vaccines for oncological indications
OncoImmunology, 2017, 6, e1398878
5.530Citations (PDF)
128Autophagie, bonne santé et longévité
Medecine/Sciences, 2017, 33, 246-251
0.23Citations (PDF)
129Robust detection of immune transcripts in FFPE samples using targeted RNA sequencing
Oncotarget, 2017, 8, 3197-3205
1.754Citations (PDF)
130The spectrum of T cell metabolism in health and disease
Nature Reviews Immunology, 2017, 18, 19-34
56.7393Citations (PDF)
131Mitochondrial metabolism and cancer
Cell Research, 2017, 28, 265-280
12.51,144Citations (PDF)
132Autophagy-dependent danger signaling and adaptive immunity to poorly immunogenic tumors
Oncotarget, 2017, 8, 5686-5691
1.713Citations (PDF)
133Lysosome-targeting agents in cancer therapy
Oncotarget, 2017, 8, 112168-112169
1.714Citations (PDF)
134Mitochondrial regulation of cell death: a phylogenetically conserved control
Microbial Cell, 2016, 3, 101-108
3.198Citations (PDF)
135Calreticulin exposure by malignant blasts correlates with robust anticancer immunity and improved clinical outcome in AML patients
Blood, 2016, 128, 3113-3124
4.2128Citations (PDF)
136Regulated cell death and adaptive stress responses
Cellular and Molecular Life Sciences, 2016, 73, 2405-2410
5.6159Citations (PDF)
137Mitochondrial Permeability Transition: New Findings and Persisting Uncertainties
Trends in Cell Biology, 2016, 26, 655-667
12.3198Citations (PDF)
138Metabolic Control of Longevity
Cell, 2016, 166, 802-821
34.1714Citations (PDF)
139Trial Watch: Immunotherapy plus radiation therapy for oncological indications
OncoImmunology, 2016, 5, e1214790
5.568Citations (PDF)
140Immunological Mechanisms Underneath the Efficacy of Cancer Therapy
Cancer Immunology Research, 2016, 4, 895-902
4.2159Citations (PDF)
141Autophagy in acute brain injury
Nature Reviews Neuroscience, 2016, 17, 467-484
24.7209Citations (PDF)
142Guidelines for the use and interpretation of assays for monitoring autophagy (3rd edition)
Autophagy, 2016, 12, 1-222
14.04,989Citations (PDF)
143Trial Watch—Immunostimulation with cytokines in cancer therapy
OncoImmunology, 2016, 5, e1115942
5.559Citations (PDF)
144Trial Watch—Oncolytic viruses and cancer therapy
OncoImmunology, 2016, 5, e1117740
5.597Citations (PDF)
145Trial Watch—Small molecules targeting the immunological tumor microenvironment for cancer therapy
OncoImmunology, 2016, 5, e1149674
5.547Citations (PDF)
146Trial Watch: Immunostimulation with Toll-like receptor agonists in cancer therapy
OncoImmunology, 2016, 5, e1088631
5.5119Citations (PDF)
147Immunogenic cell death in cancer and infectious disease
Nature Reviews Immunology, 2016, 17, 97-111
56.72,653Citations (PDF)
148Activating autophagy to potentiate immunogenic chemotherapy and radiation therapy
Nature Reviews Clinical Oncology, 2016, 14, 247-258
75.5293Citations (PDF)
149Amino acid deprivation promotes intestinal homeostasis through autophagy
Oncotarget, 2016, 7, 29877-29878
1.74Citations (PDF)
150Prognostic and Predictive Value of DAMPs and DAMP-Associated Processes in Cancer
Frontiers in Immunology, 2015, 6,
5.1156Citations (PDF)
151Molecular and Translational Classifications of DAMPs in Immunogenic Cell Death
Frontiers in Immunology, 2015, 6,
5.1365Citations (PDF)
152Combinatorial Strategies for the Induction of Immunogenic Cell Death
Frontiers in Immunology, 2015, 6,
5.1302Citations (PDF)
153Type I interferons in anticancer immunity
Nature Reviews Immunology, 2015, 15, 405-414
56.71,198Citations (PDF)
154Acetyl Coenzyme A: A Central Metabolite and Second Messenger
Cell Metabolism, 2015, 21, 805-821
26.21,247Citations (PDF)
155Immunological Effects of Conventional Chemotherapy and Targeted Anticancer Agents
Cancer Cell, 2015, 28, 690-714
38.51,406Citations (PDF)
156Trial watch: Tumor-targeting monoclonal antibodies for oncological indications
OncoImmunology, 2015, 4, e985940
5.550Citations (PDF)
157Trial Watch: Peptide-based anticancer vaccines
OncoImmunology, 2015, 4, e974411
5.5106Citations (PDF)
158Unsaturated fatty acids induce non‐canonical autophagy
EMBO Journal, 2015, 34, 1025-1041
7.4157Citations (PDF)
159Autophagy in malignant transformation and cancer progression
EMBO Journal, 2015, 34, 856-880
7.41,124Citations (PDF)
160Trial Watch: Proteasomal inhibitors for anticancer therapy
Molecular and Cellular Oncology, 2015, 2, e974463
1.818Citations (PDF)
161Trial Watch: Immunomodulatory monoclonal antibodies for oncological indications
OncoImmunology, 2015, 4, e1008814
5.5111Citations (PDF)
162Trial Watch: Immunogenic cell death inducers for anticancer chemotherapy
OncoImmunology, 2015, 4, e1008866
5.5277Citations (PDF)
163eIF2α phosphorylation as a biomarker of immunogenic cell death
Seminars in Cancer Biology, 2015, 33, 86-92
14.1104Citations (PDF)
164Karyotypic Aberrations in Oncogenesis and Cancer Therapy
Trends in Cancer, 2015, 1, 124-135
10.635Citations (PDF)
165Natural and therapy-induced immunosurveillance in breast cancer
Nature Medicine, 2015, 21, 1128-1138
39.5296Citations (PDF)
166Organelle-Specific Initiation of Autophagy
Molecular Cell, 2015, 59, 522-539
13.4194Citations (PDF)
167Trial Watch: Adoptive cell transfer for oncological indications
OncoImmunology, 2015, 4,
5.530Citations (PDF)
168Trial watch: Naked and vectored DNA-based anticancer vaccines
OncoImmunology, 2015, 4, e1026531
5.530Citations (PDF)
169Quantification of cellular viability by automated microscopy and flow cytometry
Oncotarget, 2015, 6, 9467-9475
1.722Citations (PDF)
170Defective autophagy gets to the brain
Oncotarget, 2015, 6, 39396-39397
1.74Citations (PDF)
171Classification of current anticancer immunotherapies
Oncotarget, 2014, 5, 12472-12508
1.7444Citations (PDF)
172Consensus guidelines for the detection of immunogenic cell death
OncoImmunology, 2014, 3, e955691
5.5776Citations (PDF)
173Trial Watch: Radioimmunotherapy for oncological indications
OncoImmunology, 2014, 3, e954929
5.543Citations (PDF)
174Trial Watch
OncoImmunology, 2014, 3, e27048
5.571Citations (PDF)
175Trial Watch
OncoImmunology, 2014, 3, e28185
5.537Citations (PDF)
176Trial watch: IDO inhibitors in cancer therapy
OncoImmunology, 2014, 3, e957994
5.5239Citations (PDF)
177Trial Watch
OncoImmunology, 2014, 3, e27297
5.5102Citations (PDF)
178Chloroquine and hydroxychloroquine for cancer therapy
Molecular and Cellular Oncology, 2014, 1, e29911
1.8176Citations (PDF)
179Trial Watch:
OncoImmunology, 2014, 3, e28694
5.5100Citations (PDF)
180Screening of novel immunogenic cell death inducers within the NCI Mechanistic Diversity Set
OncoImmunology, 2014, 3, e28473
5.5130Citations (PDF)
181Metabolic Control of Autophagy
Cell, 2014, 159, 1263-1276
34.1789Citations (PDF)
182Trial watch: Dendritic cell-based anticancer therapy
OncoImmunology, 2014, 3, e963424
5.564Citations (PDF)
183CCL2/CCR2-Dependent Recruitment of Functional Antigen-Presenting Cells into Tumors upon Chemotherapy
Cancer Research, 2014, 74, 436-445
0.6134Citations (PDF)
184Molecular mechanisms of regulated necrosis
Seminars in Cell and Developmental Biology, 2014, 35, 24-32
5.5236Citations (PDF)
185Trial Watch
OncoImmunology, 2014, 3, e27878
5.5145Citations (PDF)
186Metabolic control of cell death
Science, 2014, 345,
36.4595Citations (PDF)
187Impact of myeloid cells on the efficacy of anticancer chemotherapy
Current Opinion in Immunology, 2014, 30, 24-31
5.335Citations (PDF)
188Organelle-specific initiation of cell death
Nature Cell Biology, 2014, 16, 728-736
16.9216Citations (PDF)
189Trial Watch
OncoImmunology, 2014, 3, e28344
5.532Citations (PDF)
190Autophagy and Cellular Immune Responses
Immunity, 2013, 39, 211-227
23.3415Citations (PDF)
191Metabolic targets for cancer therapy
Nature Reviews Drug Discovery, 2013, 12, 829-846
82.4651Citations (PDF)
192Regulation of autophagy by stress-responsive transcription factors
Seminars in Cancer Biology, 2013, 23, 310-322
14.1235Citations (PDF)
193Immunological control of cell cycle aberrations for the avoidance of oncogenesis: the case of tetraploidy
Annals of the New York Academy of Sciences, 2013, 1284, 57-61
4.17Citations (PDF)
194Mechanism of Action of Conventional and Targeted Anticancer Therapies: Reinstating Immunosurveillance
Immunity, 2013, 39, 74-88
23.3824Citations (PDF)
195Decoding cell death signals in liver inflammation
Journal of Hepatology, 2013, 59, 583-594
3.6943Citations (PDF)
196Anticancer Chemotherapy-Induced Intratumoral Recruitment and Differentiation of Antigen-Presenting Cells
Immunity, 2013, 38, 729-741
23.3655Citations (PDF)
197Immunogenic Cell Death in Cancer Therapy
Annual Review of Immunology, 2013, 31, 51-72
30.02,994Citations (PDF)
198Crosstalk between ER stress and immunogenic cell death
Cytokine and Growth Factor Reviews, 2013, 24, 311-318
10.8218Citations (PDF)
199Trial watch
OncoImmunology, 2013, 2, e23803
5.596Citations (PDF)
200Cisplatin Resistance Associated with PARP Hyperactivation
Cancer Research, 2013, 73, 2271-2280
0.6161Citations (PDF)
201Functions of BCL-X<sub><b>L</b></sub>at the Interface between Cell Death and Metabolism
International Journal of Cell Biology, 2013, 2013, 1-10
2.278Citations (PDF)
202Trial watch
OncoImmunology, 2013, 2, e23082
5.5139Citations (PDF)
203Trial watch
OncoImmunology, 2013, 2, e25771
5.5161Citations (PDF)
204Trial Watch: Lenalidomide-based immunochemotherapy
OncoImmunology, 2013, 2, e26494
5.553Citations (PDF)
205Trial watch
OncoImmunology, 2013, 2, e22789
5.597Citations (PDF)
206Trial watch
OncoImmunology, 2013, 2, e23510
5.5164Citations (PDF)
207Trial Watch
OncoImmunology, 2013, 2, e26621
5.5103Citations (PDF)
208Trial Watch
OncoImmunology, 2013, 2, e24238
5.559Citations (PDF)
209Trial Watch
OncoImmunology, 2013, 2, e24850
5.552Citations (PDF)
210Tumor necrosis factor is dispensable for the success of immunogenic anticancer chemotherapy
OncoImmunology, 2013, 2, e24786
5.523Citations (PDF)
211Trial Watch
OncoImmunology, 2013, 2, e25595
5.585Citations (PDF)
212Trial Watch
OncoImmunology, 2013, 2, e25238
5.5142Citations (PDF)
213Trial watch
OncoImmunology, 2013, 2, e24612
5.5182Citations (PDF)
214Immunohistochemical detection of cytoplasmic LC3 puncta in human cancer specimens
Autophagy, 2012, 8, 1175-1184
14.072Citations (PDF)
215Trial watch: FDA-approved Toll-like receptor agonists for cancer therapy
OncoImmunology, 2012, 1, 894-907
5.5217Citations (PDF)
216Loss-of-function alleles of<i>P2RX7</i>and<i>TLR4</i>fail to affect the response to chemotherapy in non-small cell lung cancer
OncoImmunology, 2012, 1, 271-278
5.539Citations (PDF)
217Trial watch
OncoImmunology, 2012, 1, 179-188
5.5112Citations (PDF)
218Trial watch
OncoImmunology, 2012, 1, 1557-1576
5.5118Citations (PDF)
219Trial Watch
OncoImmunology, 2012, 1, 699-739
5.5193Citations (PDF)
220Trial Watch
OncoImmunology, 2012, 1, 306-315
5.576Citations (PDF)
221Trial Watch
OncoImmunology, 2012, 1, 493-506
5.592Citations (PDF)
222Mitochondria: master regulators of danger signalling
Nature Reviews Molecular Cell Biology, 2012, 13, 780-788
78.9685Citations (PDF)
223Cytoplasmic STAT3 Represses Autophagy by Inhibiting PKR Activity
Molecular Cell, 2012, 48, 667-680
13.4267Citations (PDF)
224Prognostic Impact of Vitamin B6 Metabolism in Lung Cancer
Cell Reports, 2012, 2, 257-269
6.4135Citations (PDF)
225Enlightening the impact of immunogenic cell death in photodynamic cancer therapy
EMBO Journal, 2012, 31, 1055-1057
7.4123Citations (PDF)
226The secret ally: immunostimulation by anticancer drugs
Nature Reviews Drug Discovery, 2012, 11, 215-233
82.4625Citations (PDF)
227Mitochondrial Control of Cellular Life, Stress, and Death
Circulation Research, 2012, 111, 1198-1207
12.5509Citations (PDF)
228Trial watch
OncoImmunology, 2012, 1, 1111-1134
5.5160Citations (PDF)
229Trial Watch: Monoclonal antibodies in cancer therapy
OncoImmunology, 2012, 1, 28-37
5.5107Citations (PDF)
230Trial watch
OncoImmunology, 2012, 1, 1323-1343
5.5223Citations (PDF)
231Inflammasomes in carcinogenesis and anticancer immune responses
Nature Immunology, 2012, 13, 343-351
24.2562Citations (PDF)
232Cardiac Glycosides Exert Anticancer Effects by Inducing Immunogenic Cell Death
Science Translational Medicine, 2012, 4,
12.7419Citations (PDF)
233Selective killing of p53‐deficient cancer cells by SP600125
EMBO Molecular Medicine, 2012, 4, 500-514
7.250Citations (PDF)
234Immunosurveillance against cancer-associated hyperploidy
Oncotarget, 2012, 3, 1270-1271
1.710Citations (PDF)
235A yeast BH3-only protein mediates the mitochondrial pathway of apoptosis
EMBO Journal, 2011, 30, 2779-2792
7.4122Citations (PDF)
236Oncosuppressive Functions of Autophagy
Antioxidants and Redox Signaling, 2011, 14, 2251-2269
6.597Citations (PDF)
237Mitochondria and the Autophagy–Inflammation–Cell Death Axis in Organismal Aging
Science, 2011, 333, 1109-1112
36.41,143Citations (PDF)
238Autophagy and innate immunity ally against bacterial invasion
EMBO Journal, 2011, 30, 3213-3214
7.430Citations (PDF)
239Mitochondrial Liaisons of p53
Antioxidants and Redox Signaling, 2011, 15, 1691-1714
6.569Citations (PDF)
240Spermidine and resveratrol induce autophagy by distinct pathways converging on the acetylproteome
Journal of Cell Biology, 2011, 192, 615-629
5.5479Citations (PDF)
241The Grand Challenges to Cellular and Molecular Oncology
Frontiers in Oncology, 2011, 1,
2.70Citations (PDF)
242Cell Death Signaling and Anticancer Therapy
Frontiers in Oncology, 2011, 1,
2.750Citations (PDF)
243Prerequisites for the Antitumor Vaccine-Like Effect of Chemotherapy and Radiotherapy
Cancer Journal (Sudbury, Mass ), 2011, 17, 351-358
1.876Citations (PDF)
244Cell death assays for drug discovery
Nature Reviews Drug Discovery, 2011, 10, 221-237
82.4522Citations (PDF)
245Mitotic catastrophe: a mechanism for avoiding genomic instability
Nature Reviews Molecular Cell Biology, 2011, 12, 385-392
78.9765Citations (PDF)
246Mitochondrial Dynamics: A Strategy for Avoiding Autophagy
Current Biology, 2011, 21, R478-R480
3.615Citations (PDF)
247Molecular determinants of immunogenic cell death elicited by anticancer chemotherapy
Cancer and Metastasis Reviews, 2011, 30, 61-69
7.2272Citations (PDF)
248Inhibition of autophagy by TAB2 and TAB3
EMBO Journal, 2011, 30, 4908-4920
7.492Citations (PDF)
249Antineoplastic activity of ouabain and pyrithione zinc in acute myeloid leukemia
Oncogene, 2011, 31, 3536-3546
6.763Citations (PDF)
250Molecular mechanisms of cisplatin resistance
Oncogene, 2011, 31, 1869-1883
6.72,416Citations (PDF)
251Liver mitochondrial membrane crosslinking and destruction in a rat model of Wilson disease
Journal of Clinical Investigation, 2011, 121, 1508-1518
10.7184Citations (PDF)
252Hormesis, cell death and aging
Aging, 2011, 3, 821-828
2.5121Citations (PDF)
253Autophagy regulation by p53
Current Opinion in Cell Biology, 2010, 22, 181-185
3.9489Citations (PDF)
254Bacterial Invasion: Linking Autophagy and Innate Immunity
Current Biology, 2010, 20, R106-R108
3.613Citations (PDF)
255Pyroptosis – a cell death modality of its kind?
European Journal of Immunology, 2010, 40, 627-630
3.2163Citations (PDF)
256The IKK complex contributes to the induction of autophagy
EMBO Journal, 2010, 29, 619-631
7.4284Citations (PDF)
257Multipolar mitosis of tetraploid cells: inhibition by p53 and dependency on Mos
EMBO Journal, 2010, 29, 1272-1284
7.4163Citations (PDF)
258Targeting mitochondria for cancer therapy
Nature Reviews Drug Discovery, 2010, 9, 447-464
82.41,524Citations (PDF)
259Molecular mechanisms of necroptosis: an ordered cellular explosion
Nature Reviews Molecular Cell Biology, 2010, 11, 700-714
78.92,149Citations (PDF)
260Surface‐exposed calreticulin in the interaction between dying cells and phagocytes
Annals of the New York Academy of Sciences, 2010, 1209, 77-82
4.1105Citations (PDF)
261miR-181a and miR-630 Regulate Cisplatin-Induced Cancer Cell Death
Cancer Research, 2010, 70, 1793-1803
0.6266Citations (PDF)
262Caloric restriction and resveratrol promote longevity through the Sirtuin-1-dependent induction of autophagy
Cell Death and Disease, 2010, 1, e10-e10
8.7569Citations (PDF)
263Mitochondrial gateways to cancer
Molecular Aspects of Medicine, 2010, 31, 1-20
9.6260Citations (PDF)
264Illicit survival of cancer cells during polyploidization and depolyploidization
Cell Death and Differentiation, 2010, 18, 1403-1413
13.7148Citations (PDF)
265TP53 and MTOR crosstalk to regulate cellular senescence
Aging, 2010, 2, 535-537
2.576Citations (PDF)
266RIP Kinases Initiate Programmed Necrosis
Journal of Molecular Cell Biology, 2009, 1, 8-10
3.6101Citations (PDF)
267Viral subversion of immunogenic cell death
Cell Cycle, 2009, 8, 860-869
3.361Citations (PDF)
268Targeting post-mitochondrial effectors of apoptosis for neuroprotection
Biochimica Et Biophysica Acta - Bioenergetics, 2009, 1787, 402-413
0.9108Citations (PDF)
269Anti- and pro-tumor functions of autophagy
Biochimica Et Biophysica Acta - Molecular Cell Research, 2009, 1793, 1524-1532
3.6348Citations (PDF)
270A chemical inhibitor of Apaf-1 exerts mitochondrioprotective functions and interferes with the intra-S-phase DNA damage checkpoint
Apoptosis: an International Journal on Programmed Cell Death, 2009, 14, 182-190
7.231Citations (PDF)
271NF-κB blockade upregulates Bax, TSP-1, and TSP-2 expression in rat granulation tissue
Journal of Molecular Medicine, 2009, 87, 481-492
3.814Citations (PDF)
272Adenine nucleotide translocase: a component of the phylogenetically conserved cell death machinery
Cell Death and Differentiation, 2009, 16, 1419-1425
13.797Citations (PDF)
273The inositol 1,4,5-trisphosphate receptor regulates autophagy through its interaction with Beclin 1
Cell Death and Differentiation, 2009, 16, 1006-1017
13.7277Citations (PDF)
274Mitochondrial membrane permeabilization in neuronal injury
Nature Reviews Neuroscience, 2009, 10, 481-494
24.7386Citations (PDF)
275Suppression of the DNA damage response in acute myeloid leukemia versus myelodysplastic syndrome
Oncogene, 2009, 28, 2205-2218
6.754Citations (PDF)
276No death without life: vital functions of apoptotic effectors
Cell Death and Differentiation, 2008, 15, 1113-1123
13.7232Citations (PDF)
277Hierarchical involvement of Bak, VDAC1 and Bax in cisplatin-induced cell death
Oncogene, 2008, 27, 4221-4232
6.7193Citations (PDF)
278Regulation of autophagy by cytoplasmic p53
Nature Cell Biology, 2008, 10, 676-687
16.91,088Citations (PDF)
279Unexpected role of the phosphate carrier in mitochondrial fragmentation
Cell Death and Differentiation, 2008, 15, 616-618
13.713Citations (PDF)
280Erlotinib and gefitinib for the treatment of myelodysplastic syndrome and acute myeloid leukemia: A preclinical comparison
Biochemical Pharmacology, 2008, 76, 1417-1425
5.231Citations (PDF)
281Chapter Eighteen Methods to Dissect Mitochondrial Membrane Permeabilization in the Course of Apoptosis
Methods in Enzymology, 2008, , 355-374
2.129Citations (PDF)
282Targeting p53 to mitochondria for cancer therapy
Cell Cycle, 2008, 7, 1949-1955
3.3112Citations (PDF)
283Viral Control of Mitochondrial Apoptosis
PLoS Pathogens, 2008, 4, e1000018
4.4406Citations (PDF)
284To Die or Not to Die: That is the Autophagic Question
Current Molecular Medicine, 2008, 8, 78-91
2.2262Citations (PDF)
285Erlotinib exhibits antineoplastic off-target effects in AML and MDS: a preclinical study
Blood, 2008, 111, 2170-2180
4.2108Citations (PDF)
286Classification of cell death: recommendations of the Nomenclature Committee on Cell Death 2009
Cell Death and Differentiation, 2008, 16, 3-11
13.72,720Citations (PDF)
287Nonapoptotic Role for Apaf-1 in the DNA Damage Checkpoint
Molecular Cell, 2007, 28, 624-637
13.4117Citations (PDF)
288Intracellular redox equilibrium and growth phase affect the performance of luciferase-based biosensors
Journal of Biotechnology, 2007, 127, 188-198
3.929Citations (PDF)
289Mitochondrial Membrane Permeabilization in Cell Death
Physiological Reviews, 2007, 87, 99-163
25.93,321Citations (PDF)
290Inhibition of Chk1 Kills Tetraploid Tumor Cells through a p53-Dependent Pathway
PLoS ONE, 2007, 2, e1337
2.468Citations (PDF)
291Methods for the assessment of mitochondrial membrane permeabilization in apoptosis
Apoptosis: an International Journal on Programmed Cell Death, 2007, 12, 803-813
7.2209Citations (PDF)
292The EGFR-Inhibitor Erlotinib Induces Differentiation, Cell Cycle Arrest and Apoptosis in EGFR-Negative Cells of MDS and AML.
Blood, 2007, 110, 399-399
4.20Citations (PDF)
293Mechanisms of cytochrome c release from mitochondria
Cell Death and Differentiation, 2006, 13, 1423-1433
13.71,251Citations (PDF)
294Mitochondria as therapeutic targets for cancer chemotherapy
Oncogene, 2006, 25, 4812-4830
6.7329Citations (PDF)
295Whole Cell Strategies Based on lux Genes for High Throughput Applications Toward New Antimicrobials
Combinatorial Chemistry and High Throughput Screening, 2006, 9, 501-514
1.536Citations (PDF)
296Mitochondrial control of cell death induced by hyperosmotic stress
Apoptosis: an International Journal on Programmed Cell Death, 2006, 12, 3-18
7.280Citations (PDF)
297Discarding multidrug resistance inducers, the possible role of a biosensing reporter in antimicrobial discovery
Luminescence, 2004, 19, 225-227
2.93Citations (PDF)
298A real-time analysis of QacR-regulated multidrug resistance in Staphylococcus aureus
Biochemical and Biophysical Research Communications, 2003, 301, 24-30
2.113Citations (PDF)
299Trial watch: Dendritic cell-based anticancer immunotherapy
OncoImmunology, 0, , e1328341
5.5101Citations (PDF)